(Q37771888)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20623207%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

review article

1 reference

title

Molecular testing in lung cancer: the time is now (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20623207%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20623207%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Charles A Powell

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20623207%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

Haiying Cheng

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20623207%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Xunhai Xu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20623207%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Balazs Halmos

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20623207%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

publication date

1 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20623207%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

published in

Current Oncology Reports

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20623207%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20623207%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

page(s)

335-348

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20623207%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20623207%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11912-010-0118-z

7 February 2020

exact match

0 references

cites work

Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-010-0118-Z

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

21 January 2018

1 reference

12 December 2020

VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab

1 reference

12 December 2020

Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.

1 reference

12 December 2020

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

12 December 2020

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

1 reference

12 December 2020

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

1 reference

12 December 2020

A mouse model for EML4-ALK-positive lung cancer

1 reference

12 December 2020

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

1 reference

12 December 2020

Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer

1 reference

12 December 2020

EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.

1 reference

12 December 2020

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

12 December 2020

The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers

1 reference

12 December 2020

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer

1 reference

12 December 2020

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

1 reference

12 December 2020

Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer

1 reference

12 December 2020

RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer

1 reference

12 December 2020

Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study

1 reference

12 December 2020

Genomics of lung cancer.

1 reference

12 December 2020

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.

1 reference

12 December 2020

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

1 reference

12 December 2020

DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.

1 reference

12 December 2020

A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer.

1 reference

12 December 2020

Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients

1 reference

12 December 2020

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

1 reference

12 December 2020

Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer

1 reference

12 December 2020

Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis

1 reference

12 December 2020

Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

1 reference

12 December 2020

Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

1 reference

12 December 2020

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors

1 reference

12 December 2020

Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.

1 reference

12 December 2020

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

1 reference

12 December 2020

The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies

1 reference

12 December 2020

RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.

1 reference

12 December 2020

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors

1 reference

12 December 2020

Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells

1 reference

12 December 2020

Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer

1 reference

12 December 2020

Epidermal growth factor receptor mutations in lung cancer

1 reference

12 December 2020

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

12 December 2020

ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer

1 reference

12 December 2020

Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.

1 reference

12 December 2020

Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.

1 reference

12 December 2020

Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer

1 reference

12 December 2020

Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer

1 reference

12 December 2020

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

12 December 2020

Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.

1 reference

12 December 2020

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

12 December 2020

EGFR antagonists in cancer treatment

1 reference

12 December 2020

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

1 reference

12 December 2020

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

1 reference

12 December 2020

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

12 December 2020

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

1 reference

12 December 2020

Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

1 reference

12 December 2020

Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients

1 reference

12 December 2020

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

12 December 2020

Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer

1 reference

12 December 2020

KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer

1 reference

12 December 2020

Molecular predictive and prognostic markers in non-small-cell lung cancer.

1 reference

12 December 2020

Detection of mutations in EGFR in circulating lung-cancer cells

1 reference

12 December 2020

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population

1 reference

12 December 2020

Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.

1 reference

12 December 2020

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.

1 reference

12 December 2020

Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer

1 reference

12 December 2020

EML4-ALK: honing in on a new target in non-small-cell lung cancer.

1 reference

12 December 2020

Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

1 reference

12 December 2020

Pathologic Diagnosis of Advanced Lung Cancer Based on Small Biopsies and Cytology: A Paradigm Shift

1 reference

12 December 2020

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

12 December 2020

Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study

1 reference

12 December 2020

K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung

1 reference

12 December 2020

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

12 December 2020

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

1 reference

12 December 2020

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

1 reference

12 December 2020

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

1 reference

12 December 2020

MET receptor tyrosine kinase

1 reference

12 December 2020

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

1 reference

12 December 2020

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial

1 reference

12 December 2020

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

1 reference

12 December 2020

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

12 December 2020

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

1 reference

12 December 2020

Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer

1 reference

12 December 2020

10.1007/S11912-010-0118-Z

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20623207%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference